BioNTech’s (BNTX) “Buy” Rating Reiterated at HC Wainwright

BioNTech (NASDAQ:BNTX)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $150.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 50.42% from the stock’s current price.

Other analysts have also issued research reports about the company. Deutsche Bank Aktiengesellschaft upped their price objective on BioNTech from $95.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, September 19th. Canaccord Genuity Group restated a “buy” rating and issued a $171.00 price target on shares of BioNTech in a research note on Thursday. HSBC lifted their price objective on shares of BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research report on Monday, October 7th. TD Cowen dropped their price objective on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a research report on Tuesday, November 5th. Finally, Hsbc Global Res raised shares of BioNTech from a “hold” rating to a “strong-buy” rating in a report on Friday, August 2nd. Four investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, BioNTech has a consensus rating of “Moderate Buy” and a consensus price target of $137.54.

BioNTech Price Performance

Shares of BNTX opened at $99.72 on Monday. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The company’s fifty day simple moving average is $113.54 and its 200 day simple moving average is $97.29. BioNTech has a 1-year low of $76.53 and a 1-year high of $131.49. The company has a market cap of $23.91 billion, a price-to-earnings ratio of -47.49 and a beta of 0.26.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, topping the consensus estimate of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. During the same period in the previous year, the business earned $0.73 EPS. BioNTech’s revenue for the quarter was up 38.9% compared to the same quarter last year. On average, research analysts forecast that BioNTech will post -3.68 earnings per share for the current fiscal year.

Institutional Trading of BioNTech

Institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC grew its position in BioNTech by 797.8% in the third quarter. FMR LLC now owns 6,299,929 shares of the company’s stock valued at $748,243,000 after acquiring an additional 5,598,190 shares during the last quarter. Fred Alger Management LLC bought a new stake in shares of BioNTech during the 3rd quarter valued at approximately $59,485,000. Candriam S.C.A. grew its holdings in shares of BioNTech by 261.2% during the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock valued at $46,526,000 after purchasing an additional 418,695 shares during the last quarter. Point72 Asset Management L.P. increased its position in BioNTech by 283.5% during the 2nd quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock worth $37,103,000 after purchasing an additional 341,311 shares in the last quarter. Finally, Braidwell LP bought a new position in BioNTech in the 3rd quarter valued at approximately $29,425,000. 15.52% of the stock is currently owned by institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.